David F Moreno

13PUBLICATIONS
70CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Medical infection agents (incl. prions)Gene and molecular therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 27, 2025
Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited.

Luis Gerardo Rodríguez-Lobato, Oriol Cardús, Joan Mañé-Pujol

|Dec 06, 2024
Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells.

Anthony M Battram, Joan Mañé-Pujol, David F Moreno

|Nov 27, 2024
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma.

Inés Zugasti, Marta Tormo-Ratera, Aina Oliver-Caldés

|Nov 13, 2024
Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry.

David F Moreno, Cristina Jiménez, Fernando Escalante

|Jul 11, 2024
Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma.

Ester Lozano, Mari-Pau Mena, Glòria Garrabou

|Mar 11, 2024
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma.

Aina Oliver-Caldes, Marta Español-Rego, Aintzane Zabaleta

Pageof 3

Frequent Collaborators

11 joint publications

Carlos Fernández de Larrea

8 joint publications

Luis-Gerardo Rodríguez-Lobato

8 joint publications

Aina Oliver-Caldés

7 joint publications

Laura Rosiñol